BioXcel Therapeutics (BTAI) Misses Q2 EPS by 245c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q2 EPS of ($2.45). Revenue for the quarter came in at $120 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Citigroup set to join top banks in Anthropic IPO - Bloomberg
• Rothschild Redburn Upgrades Equifax (EFX) to Buy
• RBC Capital Downgrades Super Retail Group Ltd. (SUL:AU) to Sector Perform